Investigating response to PARP inhibition and androgen receptor pathway inhibition in C4-2B prostate cancer cells

Use of PARP inhibitors (PARPi) has been shown effective in the management of selected patients with advanced prostate cancer. Still, it is incompletely understood how PARPi work and what mechanisms may enable adaptation and progression. This study utilized RNA-sequencing to understand response to PARP inhibition (olaparib) in regard to both intensity and duration of treatment. PARPi have also been shown to be effective when combined with androgen receptor (AR) pathway inhibitors (ARPi), but much remains unknown regarding the utility of combination regimens. We additionally performed RNA-sequencing to better define transcriptomic changes associated with either monotherapy PARPi (olaparib or talazoparib), monotherapy ARPi (abiraterone or enzalutamide), or combinations (abiraterone + olaparib, enzalutamide + talazoparib).